octanorm 16.5%

BIOLOGICAL2 trials

Sponsors

Octapharma

Conditions

Primary Immune Deficiency DisorderPrimary Immunodeficiency

Phase 3

Study of Octanorm Subcutaneous IG in Patients With PID

CompletedNCT01888484

OctapharmaPrimary Immune Deficiency Disorder

Start: 2014-03-31End: 2020-06-09Updated: 2021-08-17

CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL

CompletedNCT03907241

OctapharmaPrimary Immunodeficiency

Start: 2016-03-01End: 2019-09-05Updated: 2020-10-27

Related Papers

Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies

Frontiers in Immunology2019-02-0422 citations